| |
| Trust Performance (as of 11/22/2024) |
*Inception Date is 12/2/2022 |
| |
Cumulative Total Return |
Average Annual Total Return |
| |
YTD |
Since
Inception* |
3 mo |
6 mo |
1 yr |
3 yr |
5 yr |
10 yr |
Since
Inception* |
With Transactional
Sales Charge |
21.17% |
19.49% |
8.31% |
13.51% |
26.60% |
N/A |
N/A |
N/A |
9.43% |
Without Transactional
Sales Charge |
21.17% |
23.76% |
8.31% |
13.51% |
31.12% |
N/A |
N/A |
N/A |
11.40% |
|
| Distributions Received in Cash |
With Transactional
Sales Charge |
20.85% |
18.32% |
8.29% |
13.41% |
26.19% |
N/A |
N/A |
N/A |
8.89% |
Without Transactional
Sales Charge |
20.85% |
22.54% |
8.29% |
13.41% |
30.70% |
N/A |
N/A |
N/A |
10.84% |
|
| S&P 1500 SUPERCOMPOSITE (SPR) |
26.15% |
49.40% |
7.78% |
13.22% |
32.82% |
N/A |
N/A |
N/A |
22.54% |
|
| |
Cumulative
Total Return |
Average Annual
Total Return |
| With Transactional Sales Charge (Distributions Reinvested) |
19.49% |
|
9.43% |
|
| Without Transactional Sales Charge (Distributions Reinvested) |
23.76% |
|
11.40% |
|
| With Transactional Sales Charge (Distributions Received in Cash) |
18.32% |
|
8.89% |
|
| Without Transactional Sales Charge (Distributions Received in Cash) |
22.54% |
|
10.84% |
|
| S&P 1500 SUPERCOMPOSITE (SPR) |
49.40% |
|
22.54% |
|
|
| Sales Charges (based on a $10 public offering price) |
| Transactional Sales Charges: |
Initial: |
0.00% |
| |
Deferred: |
3.45% |
| Creation & Development Fee: |
|
0.50% |
| Maximum Sales Charge: |
|
3.95% |
|
|
| Creation & Development Fee: |
0.50% |
| Maximum Sales Charge: |
0.50% |
|
| The table above shows the initial offering period sales charge. Certain performance periods shown on this page may begin after the end of the initial offering period and reflect a secondary market sales charge. Please see the prospectus for sales charge details, including the secondary market sales charge amount applicable to a period. |
Past Performance is no indication of future results. Investment returns and principal value will fluctuate and units when sold or redeemed,
may be worth more or less than their original cost. All returns are historical and do not represent potential future performance. This report is not
and should not be construed as an offer to buy or sell securities.
Unless an index is indicated to be a price only index, all index returns assume that dividends are reinvested when they are received.
Returns With Transactional Sales Charge reflect the maximum transactional sales charge that would be payable by an investor upon sale or
redemption of units at the end of the applicable period(s). The transactional sales charge includes any initial or deferred sales charges other than the
creation and development fee. These returns do not reflect any creation and development fee prior to collection (generally the close of the initial offering period).
Any creation and development fee is reflected in the returns as of the time of payment by a trust.
Returns Without Transactional Sales Charge do not reflect any transactional sales charge and do not reflect any creation and development fee prior
to collection (generally the close of the initial offering period). Any creation and development fee is reflected in the returns as of the time of payment by a trust.
If applicable, returns shown with distributions reinvested assume distributions are reinvested on the reinvestment date.
|
Risk Considerations Equity Risk. An investment in a portfolio containing common stocks is subject to certain risks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market. Buy & Hold Risk – Taxable Trusts. This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan. COVID-19 Economic Impact Risk. The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease. Volatility Risk. The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers. Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.
You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.
This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.
Not FDIC Insured, Not Bank Guaranteed and May Lose Value.
CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.
|
|
|